-
Mashup Score: 65Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the ITMIG/ESTS Database - 2 day(s) ago
R0 resection and radiation therapy have been associated with improved OS in thymic carcinoma (TC) patients. Here we analyzed which subgroups of patients derive the greatest benefit from postoperative radiation therapy (PORT).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 75
PURPOSE The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS Patients with SCLC and progression on or after first-line platinum-based chemotherapy were randomly assigned (1:1) to intravenous (IV) liposomal irinotecan (70 mg/m2 every 2 weeks in a 6-week cycle) or IV topotecan (1.5 mg/m2 daily for 5 consecutive days, every 3 weeks in a 6-week cycle). The primary end point was overall survival (OS). Key secondary end points included progression-free survival (PFS) and objective response rate (ORR). RESULTS Among 461 randomly assigned patients, 229 received liposomal irinotecan and 232 received topotecan. The median follow-up was 18.4 months. The median OS was 7.9 months with liposomal irinotecan versus 8.3 months with topotecan (hazard ratio [HR], 1.11 [95% CI, 0.90 to 1.37]; P = .31). The median PFS per blinded independent central review (BICR) was 4.0 months with liposomal irinotecan a
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14
Anaplastic lymphoma kinase (ALK) gene rearrangements are present in 2% to 7% of the non-small cell lung cancer (NSCLC) patient population [1–3]. Identification of ALK gene rearrangements in NSCLC is clinically important as tumors harboring this genomic alteration are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) [3]. According to international guidelines, the preferred first-line treatment option for patients with ALK-positive metastatic NSCLC includes second-generation ALK TKIs, alectinib or brigatinib, or the third-generation ALK TKI, lorlatinib [4,5].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22024 Texas Lung Cancer Conference Agenda - 11 day(s) ago
2024 Texas Lung Cancer Conference Agenda @TLCconference #TexasLung24
Source: thetlcconference.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 92Completion Of Pembrolizumab In advanced non-small cell Lung cancer – real world Outcomes after Two years of therapy (COPILOT) - 11 day(s) ago
Immune checkpoint inhibitor (ICI)’s targeting the programmed-death-1/programmed-death ligand 1 (PD-1/PD-L1) axis have established themselves as part of the first line management of metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations. Pembrolizumab, an ICI directed against PD-1, has been shown in four practice changing first line phase III randomised controlled trials to improve overall survival alone, or in combination with chemotherapy, compared to chemotherapy alone in patients with advanced NSCLC1-4.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 104
Responses to first-line PD-1 inhibition vary among patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 TPS ≥50%. We previously reported improved clinical outcomes to first-line PD-1 inhibition in patients with metastatic NSCLC with a PD-L1 TPS of ≥90% vs 50-89% in a pilot study. Here, we report the three-year survival with first-line pembrolizumab and cemiplimab in two large independent cohorts of patients with PD-L1 TPS ≥90% vs 50-89% and characterize genomic and immunophenotypic differences between these PD-L1 expression groups, which were largely unknown.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 40Clinical utility of circulating tumor DNA in patients with advanced KRASG12C-mutated non-small cell lung cancer treated with sotorasib. - 12 day(s) ago
For patients with KRASG12C-mutated NSCLC who are treated with sotorasib, there is a lack of biomarkers to guide treatment decisions. We therefore investigated the clinical utility of pre-treatment and on-treatment circulating tumor DNA (ctDNA), as well as treatment-emergent alterations upon disease progression.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23
One of the most frequent oncogenic event in non-small cell lung cancer (NSCLC) is a glycine to cysteine substitution in position 12 in the V-ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene i.e., the KRASG12C mutation, detected in 13 % of the cases [1].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 55Therapy for Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights - 18 day(s) ago
The landscape of treatment options for patients with advanced non–small cell lung cancer continues to evolve rapidly, with the recently updated non–small cell lung cancer (NSCLC) living guidelines providing important recommendations and new treatment options (Figs 1 – 3). 1, 2 Keeping abreast of these changes and understanding the data and implications of the studies that lead to guideline recommendations remains a significant challenge for oncologists, who frequently encounter clinical situations for
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 96Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias - 18 day(s) ago
Immune checkpoint inhibitors (ICIs), including anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death protein–ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) antibodies, have been approved for patients with advanced or recurrent non-small cell lung cancer (NSCLC) [1–9]. However, ICIs often cause immune-related adverse events (irAEs), potentially leading to discontinuation of the treatment. A meta-analysis demonstrated that treatment discontinuation due to irAE may affect the outcome of the patient [10].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
Who benefits from post-operative radiation therapy (PORT) for thymic carcinoma? Analysis of 462 pts from ITMIG/ESTS database @JTOonline shows 5y OS rate 68% with PORT (vs 53%) with particular benefit for stage III-IV and those with R1/2 resection. https://t.co/jdcHDVOJq8